Company intelligence / Profile preview

Fuzhou Minhai Pharmaceutical Co., Ltd.

Fuqing, Fujian, Chinafzmh.com ↗

Ownership: Private
Development stage: Commercial

Overview

Fuzhou Minhai Pharmaceutical Co., Ltd. develops and manufactures generic pharmaceutical products. The company has completed clinical bioequivalence trials for at least two oral drug formulations—celecoxib capsules and roxatidine acetate hydrochloride extended-release capsules—demonstrating comparable pharmacokinetics to branded reference products in healthy volunteers. These results support regulatory filings for commercial approval.

Therapeutic areas: GastroenterologyRheumatology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

Kangguzengsheng

Unknown

Partnerships

No major international pharma partnerships disclosed; possible local collaborations with CROs or academic institutions not detailed.

Beyond the preview

Go deeper on Fuzhou Minhai Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuzhou Minhai Pharmaceutical Co., Ltd..

Explore the full profile